Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

676
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
676
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

441
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
441

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enolase from Trypanosoma cruzi is inhibited by its interaction with metallocarboxypeptidase-1 and a putative acireductone dioxygenase.

Biochimica et biophysica acta. Proteins and proteomics·2018
Same author

Epidemiological and sociodemographic factors associated with complicated alcohol withdrawal syndrome.

Revista clinica espanola·2017
Same author

[Carbapenem resistance in Pseudomonas aeruginosa isolated from urine cultures: prevalence and risk factors].

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia·2017
Same author

EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.

Oncogene·2016
Same author

Papular purpuric gloves and socks syndrome.

Revista clinica espanola·2016
Same author

Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced.

Lupus·2014

Related Experiment Video

Updated: Apr 9, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

18.2K

Dabigatran: Experience in standard clinical practice.

J Álvarez-Otero1, J de la Fuente-Aguado1, J C Arias-Castaño2

  • 1Servicio de Medicina Interna, Hospital Povisa, Vigo, España.

Revista Clinica Espanola
|June 23, 2015
PubMed
Summary
This summary is machine-generated.

Dabigatran effectively prevents stroke in patients with nonvalvular atrial fibrillation in clinical practice. This anticoagulant demonstrates a favorable safety profile, with low rates of ischemic events and manageable hemorrhagic complications.

Keywords:
AnticoagulaciónAnticoagulationAtrial fibrillationDabigatranDabigatránFibrilación auricularHaemorrhageHemorragiaIctus isquémicoIschaemic stroke

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.8K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K

Related Experiment Videos

Last Updated: Apr 9, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

18.2K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.8K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Dabigatran, a direct thrombin inhibitor, is approved for preventing ischemic stroke in nonvalvular atrial fibrillation (NVAF).
  • Real-world efficacy and safety data are crucial for understanding its clinical utility beyond trial settings.

Purpose of the Study:

  • To evaluate the effectiveness of dabigatran in preventing cerebral ischemic events in NVAF patients.
  • To assess the tolerance and safety profile of dabigatran in routine clinical practice.

Main Methods:

  • A retrospective, descriptive study analyzed 316 patients treated with dabigatran from November 2011 to September 2012.
  • Follow-up extended to June 2013, recording ischemic events (cerebral, cardiac, peripheral) and hemorrhagic complications.

Main Results:

  • The study included 316 patients (mean age 76.46±8.37 years, 53.5% male).
  • Low incidence of ischemic events: 0.55/100 patient-years for stroke and 2.18/100 patient-years for other ischemic events.
  • Hemorrhagic complications occurred in 10.91/100 patient-years, with 2.18/100 patient-years being major hemorrhages.

Conclusions:

  • Dabigatran is effective for stroke prevention in standard clinical practice for NVAF patients.
  • The observed safety profile of dabigatran aligns with findings from pivotal clinical trials.